FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295455963> ?p ?o ?g. }

• W4295455963 endingPage "810" @default.
• W4295455963 startingPage "795" @default.
• W4295455963 abstract "The dual orexin receptor antagonist daridorexant, studied in two phase III trials, dose-dependently improved objective and subjective sleep variables and daytime functioning in adults with insomnia. Because treatment of insomnia in older adults is challenging and has limited options, the purpose of the current analysis was to further analyse the phase III trial studying the higher doses of daridorexant, those that showed efficacy (daridorexant 50 mg, daridorexant 25 mg and placebo, nightly for 3 months), and compare the safety and efficacy of daridorexant in patients aged ≥ 65 (‘older adults’) to those aged < 65 years (‘younger adults’). Analyses by age (≥ 65 years, n = 364; < 65 years, n = 566) were performed on data from the randomised, double-blind, placebo-controlled Trial 1 in adult patients with insomnia (NCT03545191). Efficacy endpoints included a change from baseline at month 1 and month 3 in polysomnography-measured wake after sleep onset (WASO) and latency to persistent sleep (LPS), self-reported total sleep time (sTST) and daytime functioning assessed using the validated Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ). Safety endpoints included adverse events and the Visual Analog Scale for morning sleepiness. At baseline, mean [standard deviation] WASO was numerically greater (110 [39] vs 92 [38] min) in older than younger adults, while LPS was comparable (~ 65 min). Mean baseline IDSIQ total and all domain scores were numerically lower (i.e. better) in older adults. Daridorexant caused similar reductions in WASO and LPS, and similar increases in sTST, from baseline, in both age groups; improvements were numerically greater with daridorexant 50 mg than 25 mg. At month 3, daridorexant 50 mg, compared with placebo, decreased WASO by a least-squares mean of 19.6 (95% confidence interval 9.7, 29.5) in older patients versus 17.4 min (10.7, 24.0) in younger patients and decreased LPS by a least-squares mean of 14.9 (7.5, 22.3) in older patients versus 9.7 min (3.7, 15.7) in younger patients. Daridorexant 50 mg increased sTST from baseline to month 3 by a least-squares mean of 59.9 (49.6, 70.3) in older patients versus 57.1 min (48.9, 65.3) in younger patients. Daridorexant 50 mg progressively improved IDSIQ total and domain scores from week 1 onwards similarly in both groups; daridorexant 25 mg improved IDSIQ scores, but only in younger adults. In both age groups, in comparison with placebo, the overall incidence of adverse events was comparable, and there were fewer falls on daridorexant. Daridorexant improved Visual Analog Scale morning sleepiness in both groups; daridorexant 50 mg increased the mean (standard deviation) Visual Analog Scale morning sleepiness score by 15.9 (20.7) in older adults and by 14.9 (18.7) in younger adults from baseline to month 3. In older adults, there was one case of sleep paralysis, and no cases of narcolepsy, cataplexy, or complex sleep behaviour. In older patients with insomnia, as in younger patients, the efficacy of daridorexant is maximal on night-time and daytime variables at the higher dose of 50 mg. Older patients particularly require this dose to improve daytime functioning. Older patients are not at an increased risk of adverse events or residual effects the next morning after night-time administration of daridorexant, even at 50 mg. The dose of daridorexant does not need to be decreased for older patients. ClinicalTrials.gov (NCT03545191) [first posted: 4 June, 4 2018], https://clinicaltrials.gov/ct2/show/NCT03545191 . The burden of chronic insomnia (difficulty in falling/staying asleep or not getting enough sleep) increases with age yet treatment options in older patients are limited. In older patients, because of a risk of side effects, guidelines suggest caution when prescribing sleep medications and, for some drugs, recommend starting at a lower dose. Daridorexant was approved in 2022 for the treatment of insomnia in adults following positive results in two trials that showed daridorexant significantly improved night-time sleep and daytime functioning over 3 months of treatment in adults with insomnia. Approximately 40% of patients taking part in these trials were aged 65 years or older. This current analysis compared the safety and benefits of daridorexant in older adults (aged at least 65 years) and younger adults (aged less than 65 years) in the trial that administered the highest two doses of daridorexant, 25 and 50 mg. The results showed that the benefits of daridorexant were comparable in both age groups over 3 months; compared with placebo, daridorexant improved night-time sleep (reduced time awake during the night, reduced time to fall asleep and increased total sleep time) and daytime functioning—patients had less daytime sleepiness and a better mood and feeling of alertness. In older patients, the benefits, particularly for daytime functioning, were greatest at the higher 50-mg dose, without any increase in side effects. Both doses of daridorexant were equally well tolerated in the two age groups, indicating that treatment with daridorexant at 50 mg can be safely started in older patients." @default.
• W4295455963 created "2022-09-14" @default.
• W4295455963 creator A5001010314 @default.
• W4295455963 creator A5011364353 @default.
• W4295455963 creator A5021471052 @default.
• W4295455963 creator A5046780212 @default.
• W4295455963 creator A5084588041 @default.
• W4295455963 creator A5087471581 @default.
• W4295455963 date "2022-09-13" @default.
• W4295455963 modified "2023-10-09" @default.
• W4295455963 title "Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial" @default.
• W4295455963 cites W182910583 @default.
• W4295455963 cites W195896834 @default.
• W4295455963 cites W1969982801 @default.
• W4295455963 cites W1986079811 @default.
• W4295455963 cites W2031570679 @default.
• W4295455963 cites W2062127507 @default.
• W4295455963 cites W2064883756 @default.
• W4295455963 cites W2081413435 @default.
• W4295455963 cites W2081558704 @default.
• W4295455963 cites W2098705260 @default.
• W4295455963 cites W2101264963 @default.
• W4295455963 cites W2108963305 @default.
• W4295455963 cites W2115924191 @default.
• W4295455963 cites W2129357751 @default.
• W4295455963 cites W2153336503 @default.
• W4295455963 cites W2155139777 @default.
• W4295455963 cites W2161358611 @default.
• W4295455963 cites W2347166707 @default.
• W4295455963 cites W2546647298 @default.
• W4295455963 cites W2578164715 @default.
• W4295455963 cites W2605277320 @default.
• W4295455963 cites W2729626603 @default.
• W4295455963 cites W2733785551 @default.
• W4295455963 cites W2768763253 @default.
• W4295455963 cites W2769640358 @default.
• W4295455963 cites W2790038805 @default.
• W4295455963 cites W2795657325 @default.
• W4295455963 cites W2802687202 @default.
• W4295455963 cites W2807387441 @default.
• W4295455963 cites W2808673984 @default.
• W4295455963 cites W2887339018 @default.
• W4295455963 cites W2894958559 @default.
• W4295455963 cites W2922860263 @default.
• W4295455963 cites W2952876617 @default.
• W4295455963 cites W2981776327 @default.
• W4295455963 cites W2989150064 @default.
• W4295455963 cites W2998868914 @default.
• W4295455963 cites W3013615956 @default.
• W4295455963 cites W3018828955 @default.
• W4295455963 cites W3082098548 @default.
• W4295455963 cites W3095371938 @default.
• W4295455963 cites W3096438267 @default.
• W4295455963 cites W3103896435 @default.
• W4295455963 cites W3133734645 @default.
• W4295455963 cites W3134232610 @default.
• W4295455963 cites W3150159407 @default.
• W4295455963 cites W3191804408 @default.
• W4295455963 cites W3198121616 @default.
• W4295455963 cites W4206262095 @default.
• W4295455963 cites W4213447589 @default.
• W4295455963 cites W4214702851 @default.
• W4295455963 cites W4220658953 @default.
• W4295455963 cites W4225278349 @default.
• W4295455963 cites W4241984066 @default.
• W4295455963 cites W4247665917 @default.
• W4295455963 cites W4286432739 @default.
• W4295455963 cites W4297820753 @default.
• W4295455963 cites W563365609 @default.
• W4295455963 doi "https://doi.org/10.1007/s40266-022-00977-4" @default.
• W4295455963 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36098936" @default.
• W4295455963 hasPublicationYear "2022" @default.
• W4295455963 type Work @default.
• W4295455963 citedByCount "9" @default.
• W4295455963 countsByYear W42954559632023 @default.
• W4295455963 crossrefType "journal-article" @default.
• W4295455963 hasAuthorship W4295455963A5001010314 @default.
• W4295455963 hasAuthorship W4295455963A5011364353 @default.
• W4295455963 hasAuthorship W4295455963A5021471052 @default.
• W4295455963 hasAuthorship W4295455963A5046780212 @default.
• W4295455963 hasAuthorship W4295455963A5084588041 @default.
• W4295455963 hasAuthorship W4295455963A5087471581 @default.
• W4295455963 hasBestOaLocation W42954559631 @default.
• W4295455963 hasConcept C118552586 @default.
• W4295455963 hasConcept C126322002 @default.
• W4295455963 hasConcept C142724271 @default.
• W4295455963 hasConcept C1513209611 @default.
• W4295455963 hasConcept C168563851 @default.
• W4295455963 hasConcept C1862650 @default.
• W4295455963 hasConcept C197934379 @default.
• W4295455963 hasConcept C204787440 @default.
• W4295455963 hasConcept C27081682 @default.
• W4295455963 hasConcept C2778205975 @default.
• W4295455963 hasConcept C2779034229 @default.
• W4295455963 hasConcept C2781053850 @default.
• W4295455963 hasConcept C2781210498 @default.
• W4295455963 hasConcept C2781326671 @default.
• W4295455963 hasConcept C2781433485 @default.

• next